| Recruiting | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymp Chronic Lymphocytic Leukemia, B-cell Malignancies | Phase 2 | 2026-02-01 |
| Completed | Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies Solid Tumor | Phase 1 | 2020-09-22 |
| Suspended | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) o Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2020-07-06 |
| Recruiting | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractor Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma | Phase 1 / Phase 2 | 2017-12-28 |
| Completed | Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC A Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | Phase 2 | 2016-07-01 |
| Completed | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lym Advanced Solid Tumors or Lymphomas | Phase 1 | 2016-05-01 |
| Completed | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer, Solid Tumors | Phase 1 | 2014-11-01 |
| Terminated | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Lymphoma | Phase 1 | 2013-07-01 |
| Completed | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymp Lymphoma, Relapsed Lymphoma, Refractory Lymphoma | Phase 1 | 2012-12-01 |
| Terminated | Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Canc Cancer | Phase 1 | 2012-09-01 |
| Completed | Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer Head and Neck Cancer | Phase 1 | 2011-11-01 |
| Completed | A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Head and Neck Cancer, Liver Cancer, Breast Cancer | Phase 1 | 2010-07-01 |
| Completed | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Tumors | Phase 1 | 2008-08-01 |